Financials data is unavailable for this security.
View more
Year on year Double Bond Pharmaceutical International AB (publ) had net income fall 14.36% from a loss of 15.16m to a larger loss of 17.34m despite a 10.25% increase in revenues from 1.24m to 1.37m. An increase in the selling, general and administrative costs as a percentage of sales from 406.31% to 408.32% was a component in the falling net income despite rising revenues.
| Gross margin | -344.65% |
|---|---|
| Net profit margin | -1,395.47% |
| Operating margin | -805.41% |
| Return on assets | -132.48% |
|---|---|
| Return on equity | -176.94% |
| Return on investment | -176.94% |
More ▼
Cash flow in SEKView more
In 2023, Double Bond Pharmaceutical International AB (publ) increased its cash reserves by 54.19%, or 1.33m. Cash Flow from Financing totalled 10.62m or 775.12% of revenues. In addition the company used 3.08m for operations while cash used for investing totalled 6.21m.
| Cash flow per share | -0.1725 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 0.0351 |
|---|---|
| Tangible book value per share | 0.0337 |
More ▼
Balance sheet in SEKView more
| Current ratio | 1.12 |
|---|---|
| Quick ratio | 1.12 |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
